Rachel Victoria Reynolds, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acne Vulgaris | 8 | 2024 | 355 | 3.100 |
Why?
|
Polycystic Ovary Syndrome | 3 | 2019 | 378 | 1.190 |
Why?
|
Dermatologic Agents | 3 | 2024 | 306 | 1.140 |
Why?
|
Dermatology | 6 | 2021 | 914 | 1.030 |
Why?
|
Spironolactone | 3 | 2024 | 411 | 0.920 |
Why?
|
Benzoyl Peroxide | 1 | 2024 | 22 | 0.910 |
Why?
|
Salicylic Acid | 1 | 2024 | 64 | 0.910 |
Why?
|
Dicarboxylic Acids | 1 | 2024 | 77 | 0.890 |
Why?
|
Isotretinoin | 2 | 2024 | 131 | 0.860 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2022 | 26 | 0.800 |
Why?
|
Doxycycline | 1 | 2024 | 337 | 0.800 |
Why?
|
Hirsutism | 3 | 2019 | 68 | 0.770 |
Why?
|
Intrauterine Devices | 1 | 2022 | 114 | 0.730 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2024 | 116 | 0.660 |
Why?
|
Professional Autonomy | 1 | 2019 | 171 | 0.590 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2019 | 389 | 0.550 |
Why?
|
Hyperandrogenism | 1 | 2014 | 39 | 0.470 |
Why?
|
Endocrine System Diseases | 1 | 2016 | 251 | 0.450 |
Why?
|
Alopecia | 2 | 2014 | 415 | 0.430 |
Why?
|
Anti-Bacterial Agents | 3 | 2024 | 7400 | 0.420 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2009 | 14 | 0.340 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7468 | 0.320 |
Why?
|
Naphthalenes | 1 | 2009 | 198 | 0.320 |
Why?
|
Methylprednisolone | 1 | 2009 | 384 | 0.300 |
Why?
|
Administration, Cutaneous | 2 | 2024 | 711 | 0.300 |
Why?
|
Antifungal Agents | 1 | 2009 | 746 | 0.240 |
Why?
|
Cortodoxone | 1 | 2024 | 17 | 0.240 |
Why?
|
Tetracyclines | 1 | 2024 | 65 | 0.230 |
Why?
|
Retinoids | 1 | 2024 | 98 | 0.220 |
Why?
|
Propionates | 1 | 2024 | 182 | 0.220 |
Why?
|
Injections, Intralesional | 1 | 2024 | 278 | 0.210 |
Why?
|
Minocycline | 1 | 2024 | 168 | 0.210 |
Why?
|
Skin | 1 | 2016 | 4468 | 0.200 |
Why?
|
Skin Diseases | 2 | 2021 | 1089 | 0.200 |
Why?
|
Internship and Residency | 2 | 2019 | 5867 | 0.190 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2022 | 190 | 0.180 |
Why?
|
Anti-Inflammatory Agents | 1 | 2009 | 1799 | 0.170 |
Why?
|
Drug Therapy, Combination | 2 | 2024 | 6499 | 0.170 |
Why?
|
Administration, Oral | 2 | 2024 | 4044 | 0.150 |
Why?
|
Immunosuppressive Agents | 1 | 2009 | 4168 | 0.140 |
Why?
|
Appointments and Schedules | 1 | 2019 | 443 | 0.130 |
Why?
|
Acanthosis Nigricans | 1 | 2014 | 47 | 0.120 |
Why?
|
Propionibacterium acnes | 1 | 2014 | 65 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 1 | 2024 | 1870 | 0.120 |
Why?
|
Flutamide | 1 | 2014 | 95 | 0.120 |
Why?
|
Phototherapy | 1 | 2017 | 367 | 0.120 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2014 | 240 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 3696 | 0.110 |
Why?
|
Finasteride | 1 | 2014 | 90 | 0.110 |
Why?
|
Telemedicine | 2 | 2021 | 3005 | 0.110 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2014 | 117 | 0.110 |
Why?
|
Prolactin | 1 | 2014 | 621 | 0.100 |
Why?
|
Perception | 1 | 2019 | 1194 | 0.100 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2014 | 546 | 0.100 |
Why?
|
Thiazolidinediones | 1 | 2014 | 465 | 0.100 |
Why?
|
Clobetasol | 1 | 2009 | 32 | 0.080 |
Why?
|
Diphenhydramine | 1 | 2009 | 63 | 0.080 |
Why?
|
Onychomycosis | 1 | 2009 | 50 | 0.080 |
Why?
|
Humans | 16 | 2024 | 760261 | 0.080 |
Why?
|
Photochemotherapy | 1 | 2014 | 819 | 0.080 |
Why?
|
Metformin | 1 | 2014 | 912 | 0.070 |
Why?
|
Medicaid | 1 | 2019 | 2811 | 0.070 |
Why?
|
Androgen Antagonists | 1 | 2014 | 1439 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3870 | 0.060 |
Why?
|
Prednisone | 1 | 2009 | 1566 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2235 | 0.060 |
Why?
|
Iodide Peroxidase | 1 | 1995 | 294 | 0.060 |
Why?
|
Testosterone | 1 | 2014 | 2469 | 0.060 |
Why?
|
Amino Acids, Diamino | 1 | 1993 | 16 | 0.060 |
Why?
|
Cystine | 1 | 1993 | 94 | 0.050 |
Why?
|
Life Style | 1 | 2014 | 3888 | 0.050 |
Why?
|
Female | 8 | 2022 | 391011 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2014 | 3046 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Fatigue | 1 | 2009 | 1544 | 0.050 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1993 | 313 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 3149 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5960 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8621 | 0.040 |
Why?
|
Amino Acids | 1 | 1993 | 1715 | 0.040 |
Why?
|
Models, Organizational | 1 | 2020 | 545 | 0.030 |
Why?
|
Pain | 1 | 2009 | 5066 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 697 | 0.030 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.030 |
Why?
|
Obesity | 1 | 2014 | 12915 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2019 | 80301 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 2 | 1995 | 2755 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1993 | 4938 | 0.020 |
Why?
|
DNA | 1 | 1993 | 7236 | 0.020 |
Why?
|
Patient Compliance | 1 | 2019 | 2689 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15740 | 0.020 |
Why?
|
Kidney | 1 | 1993 | 7072 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 1995 | 4625 | 0.020 |
Why?
|
Restriction Mapping | 1 | 1995 | 852 | 0.020 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1995 | 761 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 1995 | 915 | 0.010 |
Why?
|
Recurrence | 1 | 2016 | 8487 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1995 | 783 | 0.010 |
Why?
|
Amino Acid Transport Systems | 1 | 1993 | 35 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1993 | 422 | 0.010 |
Why?
|
Introns | 1 | 1995 | 978 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 1995 | 13456 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 1995 | 1760 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1995 | 1993 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1995 | 17628 | 0.010 |
Why?
|
Genes | 1 | 1995 | 1845 | 0.010 |
Why?
|
Middle Aged | 2 | 2020 | 220175 | 0.010 |
Why?
|
Xenopus | 1 | 1993 | 717 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1995 | 2178 | 0.010 |
Why?
|
DNA Primers | 1 | 1995 | 2819 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 1995 | 7593 | 0.010 |
Why?
|
Gene Library | 1 | 1993 | 1060 | 0.010 |
Why?
|
Cricetinae | 1 | 1993 | 2427 | 0.010 |
Why?
|
Exons | 1 | 1995 | 2391 | 0.010 |
Why?
|
Biological Transport | 1 | 1993 | 2087 | 0.010 |
Why?
|
Oocytes | 1 | 1993 | 1165 | 0.010 |
Why?
|
Rats | 2 | 1995 | 23695 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1993 | 4172 | 0.010 |
Why?
|
Rabbits | 1 | 1993 | 4773 | 0.010 |
Why?
|
Kinetics | 1 | 1993 | 6378 | 0.010 |
Why?
|
Risk Assessment | 1 | 2016 | 24086 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39254 | 0.010 |
Why?
|
Base Sequence | 1 | 1995 | 12447 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 1995 | 5784 | 0.010 |
Why?
|
Child | 1 | 2019 | 79758 | 0.010 |
Why?
|
United States | 1 | 2017 | 72363 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 58673 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2016 | 64947 | 0.010 |
Why?
|
Male | 2 | 2017 | 359413 | 0.000 |
Why?
|
Adolescent | 1 | 2016 | 87747 | 0.000 |
Why?
|
Aged | 1 | 2020 | 168995 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1995 | 22025 | 0.000 |
Why?
|
Animals | 2 | 1995 | 167940 | 0.000 |
Why?
|
Adult | 1 | 2016 | 219847 | 0.000 |
Why?
|
Mice | 1 | 1995 | 81216 | 0.000 |
Why?
|